Galiximab pharmacokinetics determined in patients with relapsed or refractory follicular NHL

被引：0
|
作者：
Woodworth, J
Peltz, EH
Leonard, JP
Friedberg, J
Younes, A
Fisher, D
Gordon, L
Leigh, BR
机构：
[1] Biogen Idec, Cambridge, MA USA
[2] Well Cornell Med Ctr, New York, NY USA
[3] Univ Rochester, Rochester, NY USA
[4] MDACC, Houston, TX USA
[5] Dana Farber Canc Inst, Boston, MA 02115 USA
[6] Northwestern Univ, Chicago, IL 60611 USA
来源：
ANNALS OF ONCOLOGY | 2005年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
585
引用
收藏
页码：208 / 208
页数：1
相关论文
共 50 条
  • [1] Updated results from a phase II study of galiximab (anti-CD80) in combination with rituximab for relapsed or refractory, follicular NHL.
    Friedberg, JW
    Leonard, JP
    Younes, A
    Fisher, DC
    Gordon, LI
    Moore, JO
    Czucznan, MS
    Miller, TP
    Stiff, PJ
    Cheson, BD
    Forero-Torres, A
    Finucane, DM
    Leigh, BR
    Molina, A
    BLOOD, 2005, 106 (11) : 685A - 685A
  • [2] Initial trials of anti-CD80 monoclonal antibody (Galiximab) therapy for patients with relapsed or refractory follicular lymphoma
    Younes, A
    Hariharan, K
    Allen, RS
    Leigh, BR
    CLINICAL LYMPHOMA, 2003, 3 (04): : 257 - 259
  • [3] Results from a phase I/II study of galiximab (anti-CD80) in combination with rituximab (anti-CD20) for relapsed or refractory, follicular NHL
    Leonard, J
    Friedberg, J
    Younes, A
    Fisher, D
    Gordon, L
    Moore, J
    Czuczman, M
    Miller, T
    Stiff, P
    Cheson, B
    Forero-Torres, A
    Nasizadeh, H
    Whiteley, M
    Leigh, BR
    ANNALS OF ONCOLOGY, 2005, 16 : 71 - 71
  • [4] Phase I/II study of galiximab, an Anti-CD80 antibody, for relapsed or refractory follicular lymphoma
    Czuczman, MS
    Thall, A
    Witzig, TE
    Vose, JM
    Younes, A
    Emmanouilides, C
    Miller, TP
    Moore, JO
    Leonard, JP
    Gordon, LI
    Sweetenham, J
    Alkuzweny, B
    Finucane, DM
    Leigh, BR
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (19) : 4390 - 4398
  • [5] Galiximab (IDEC-114) a novel antibody targeting CD80, is active in relapsed/refractory follicular lymphoma
    不详
    CLINICAL LYMPHOMA, 2003, 4 (01): : 12 - 12
  • [6] ETHNIC SENSITIVITY ASSESSMENT OF MOSUNETUZUMAB PHARMACOKINETICS (PK) IN CHINESE PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (FL).
    Liao, M.
    Li, J.
    Wilkins, J.
    Wang, B.
    Vadhavkar, S.
    Peng, K.
    Zhang, Y.
    Li, D.
    Zhou, M.
    Li, C.
    Li, C.
    Turner, D.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S12 - S12
  • [7] Treatment selection for patients with relapsed or refractory follicular lymphoma
    Skarbnik, Alan Z.
    Patel, Krish
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [8] Treatment Selection in Patients With Relapsed or Refractory Follicular Lymphoma
    Pagel, John M.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (12) : 11 - 14
  • [9] Copanlisib in patients with relapsed or refractory follicular lymphoma.
    Dreyling, Martin H.
    Santoro, Armando
    Leppa, Sirpa
    Demeter, Judit
    Follows, George
    Lenz, Georg
    Kim, Won Seog
    Mollica, Luigina
    Nagler, Arnon
    Diong, Colin Phipps
    Provencio, Mariano
    Stevens, Don A.
    Trevarthen, David
    Magagnoli, Massimo
    Cupit, Lisa
    Yin, Shuxin
    Hiemeyer, Florian
    -Vargas, Jose E. Garcia
    Childs, Barrett H.
    Zinzani, Pier Luigi
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [10] A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma
    Leonard, J. P.
    Friedberg, J. W.
    Younes, A.
    Fisher, D.
    Gordon, L. I.
    Moore, J.
    Czuczman, M.
    Miller, T.
    Stiff, P.
    Cheson, B. D.
    Forero-Torres, A.
    Chieffo, N.
    McKinney, B.
    Finucane, D.
    Molina, A.
    ANNALS OF ONCOLOGY, 2007, 18 (07) : 1216 - 1223
12345